Literature DB >> 23897320

Chronic kidney disease: epic battles in the phosphate-binder wars-the last episode?

Adrian Covic1, Luminita Voroneanu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23897320     DOI： 10.1038/nrneph.2013.149

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.

Authors:  G A Block; P Raggi; A Bellasi; L Kooienga; D M Spiegel
Journal:  Kidney Int       Date:  2007-01-03       Impact factor: 10.612

2.  Mortality in kidney disease patients treated with phosphate binders: a randomized study.

Authors:  Biagio Di Iorio; Antonio Bellasi; Domenico Russo
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 8.237

3.  Prescribed dietary phosphate restriction and survival among hemodialysis patients.

Authors:  Katherine E Lynch; Rebecca Lynch; Gary C Curhan; Steven M Brunelli
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 8.237

4.  Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Authors:  Mario Cozzolino; Maria Antonietta Rizzo; Andrea Stucchi; Daniele Cusi; Maurizio Gallieni
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

5.  A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

Authors:  Wendy L St Peter; Jiannong Liu; Eric Weinhandl; Qiao Fan
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

6.  Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

Authors:  Johan Ärnlöv; Axel C Carlsson; Johan Sundström; Erik Ingelsson; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-18       Impact factor: 8.237

7.  Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.

Authors:  Biagio Di Iorio; Donald Molony; Cynthia Bell; Emanuele Cucciniello; Vincenzo Bellizzi; Domenico Russo; Antonio Bellasi
Journal:  Am J Kidney Dis       Date:  2013-05-16       Impact factor: 8.860

8.  Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.

Authors:  Ravi Dhingra; Lisa M Sullivan; Caroline S Fox; Thomas J Wang; Ralph B D'Agostino; J Michael Gaziano; Ramachandran S Vasan
Journal:  Arch Intern Med       Date:  2007-05-14

9.  A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.

Authors:  Lisa Bernard; David Mendelssohn; Elizabeth Dunn; Colin Hutchison; Daniel T Grima
Journal:  J Med Econ       Date:  2012-09-10       Impact factor: 2.448

Review 10.  Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.

Authors:  Adrian Covic; Prajesh Kothawala; Myriam Bernal; Sean Robbins; Arpi Chalian; David Goldsmith
Journal:  Nephrol Dial Transplant       Date:  2008-11-11       Impact factor: 5.992
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.